Small Cell Lung Cancer

The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced solid tumors.

Joe Leach, MD, discusses some of the latest developments in incorporating immunotherapy into small cell lung cancer treatment regimens.

The panelist discusses how, expanding clinical trials, biomarker testing, and financial support improves access to emerging EGFR therapies. Novel bispecific antibodies and ADCs may shift treatment. Key insights include resistance monitoring and proactive AE management.

The panelist discusses how, Healthcare professionals use osimertinib 1L for EGFR-mutated NSCLC, re-testing at progression for resistance mutations. MARIPOSA data refine 1L choices by predicting resistance pathways, guiding optimal sequencing.

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing cancers.

David Spigel, MD, discusses the findings from and methodology behind the ADRIATIC study of durvalumab as consolidation therapy for patients with limited-stage small cell lung cancer.

The panelist discusses how, Healthcare professionals manage distinct toxicities with ami+laz (IRRs, rash) and osi+chemotherapyctx (cytopenias, diarrhea, fatigue). SKIPPirr informs IRR mitigation in ami’s first infusion. Proactive AE strategies include premedication, dose adjustments, supportive care, and monitoring.

The panelist discusses how, regarding the patient case, she will review the FDA approved options for the patient, including the combination of amivantamab + Lazertinib, osimertinib/chemotherapy, or single agent osimertinib.

The panelist discusses how, when discussing first-line treatment decisions for cancer patients, healthcare professionals primarily consider patient-specific factors like disease stage, molecular profile, comorbidities, and performance status. When discussing options with high-risk patients, healthcare professionals typically take a shared decision-making approach, thoroughly explaining both potential benefits and side effect management strategies. These conversations weigh factors like quality-of-life impact, monitoring requirements, and individual patient preferences to arrive at an optimal treatment strategy.

Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient presents to her primary care physician (PCP) with continued dry cough, dyspnea, and weight loss. She has a history of hypertension, previously managed on an ACE inhibitor, but is now on atenolol.

225Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment of SCLC.

Ticiana Leal, MD, discussed the case of a 73-Year-Old woman with progressive extensive-stage small cell lung cancer.

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in patients with extensive-stage small cell lung cancer and Merkel cell carcinoma.

Ariel Lopez-Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

The investigational new drug application for the nanoparticle drug SNB-101 has been cleared for small cell lung cancer treatment.

The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small cell lung cancer and other solid tumor indications.

Joe Leach, MD, discusses how comprehensive biomarker testing has impacted treatment selection for patients with small cell lung cancer.

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum chemotherapy, supported by promising antitumor activity in the phase 2 TROPiCS-03 study.

Data from the phase 1 Acclaim-3 trial of quaratusugene ozeplasmid plus atezolizumab in extensive-stage small cell lung cancer showed no dose-limiting toxicities, with the recommended dose set at 0.12 mg/kg for phase 2.

The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.

Ariel Lopez-Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have progressed after first-line chemotherapy.

In an interview with Targeted Oncology, Ariel Lopez-Chavez, MD, discussed recent developments in the small cell lung cancer space.

Ariel Lopez-Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

Antonious Hazim, MD, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.

The 0.09 mg/kg dose group of the phase 1 dose-escalation portion of the Acclaim-3 study in extensive-stage small cell lung cancer is completed.